{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:00Z","timestamp":1790899320660,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/md.0000000000005946","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T05:40:22Z","timestamp":1484718022000},"page":"e5946","source":"Crossref","is-referenced-by-count":15,"title":["The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients"],"prefix":"10.1097","volume":"96","author":[{"given":"Xue-Miao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Lian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Mei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-35-20210309","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.med.57.121304.131240","article-title":"Cardiotoxicity induced by chemotherapy and antibody therapy","volume":"57","author":"Yeh","year":"2006","journal-title":"Annu Rev Med"},{"key":"R2-35-20210309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/annonc\/mdq295","article-title":"Cardiotoxicity","volume":"21","author":"Brana","year":"2010","journal-title":"Ann Oncol"},{"key":"R3-35-20210309","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R4-35-20210309","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2013.02.007","article-title":"State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review","volume":"88","author":"Berardi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R5-35-20210309","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11739-011-0744-y","article-title":"Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology","volume":"7","author":"Raschi","year":"2012","journal-title":"Intern Emerg Med"},{"key":"R6-35-20210309","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin Cancer Res"},{"key":"R7-35-20210309","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-35-20210309","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-35-20210309","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"R10-35-20210309","doi-asserted-by":"crossref","first-page":"11741","DOI":"10.1007\/s13277-014-2227-z","article-title":"Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials","volume":"35","author":"Lv","year":"2014","journal-title":"Tumour Biol"},{"key":"R11-35-20210309","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R12-35-20210309","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-35-20210309","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"R14-35-20210309","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R15-35-20210309","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"R16-35-20210309","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"R17-35-20210309","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays","volume":"361","author":"Reichlin","year":"2009","journal-title":"N Engl J Med"},{"key":"R18-35-20210309","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00392-012-0469-6","article-title":"Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive cardiac troponin I assay in patients with acute coronary syndrome","volume":"101","author":"Mueller","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"R19-35-20210309","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0002-9149(00)01532-0","article-title":"Usefulness of ST depression in ventricular premature complexes to predict myocardial ischemia","volume":"87","author":"Rasouli","year":"2001","journal-title":"Am J Cardiol"},{"key":"R20-35-20210309","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1046\/j.1540-8167.2004.04072.x","article-title":"Mechanism for ST depression associated with contiguous subendocardial ischemia","volume":"15","author":"Hopenfeld","year":"2004","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R21-35-20210309","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tips.2003.10.002","article-title":"Assessing predictors of drug-induced torsade de pointes","volume":"24","author":"Belardinelli","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"R22-35-20210309","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.hrthm.2004.10.032","article-title":"Use of preclinical assays to predict risk of drug-induced torsades de pointes","volume":"2","author":"Belardinelli","year":"2005","journal-title":"Heart Rhythm"},{"key":"R23-35-20210309","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00280-013-2146-5","article-title":"Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors","volume":"71","author":"Deeken","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R24-35-20210309","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fca.11.54","article-title":"Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors","volume":"7","author":"Albini","year":"2011","journal-title":"Future Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:24Z","timestamp":1620960144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201701200-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005946","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}